A bioethicist explains why Kalshi's new FDA approval and clinical trial betting markets raise concerns about bias, herd behavior, and insider trading.
Jonathon Kimmelman, PhD
Advertisement
Jonathon Kimmleman, PhD, is a professor of biomedical ethics and associate member of the Department of Experimental Medicine at McGill University.
Articles by Jonathon Kimmelman, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Treatment for Sanfilippo Syndrome Type A
2
Real-World Data: FACT vs Non-FACT CAR T Outcomes Compared
3
World Alzheimer Day: Young-Onset Alzheimer Disease Often Misdiagnosed
4
FDA Approves Imlunestrant Plus Abemaciclib for Breast Cancer
5